ARTHEx raises Series B for clinical trial of ASO in myotonic dystrophy

ARTHEx Biotech has raised €42 million (about $46 million) in Series B funds to bankroll an early-stage study of a drug candidate in myotonic dystrophy type 1, or DM1. The Valencia, Spain-based startup will enter the clinic in the second half of this year with an IV-delivered drug candidate for…